Cancer immunotherapy has transformed modern oncology by harnessing the body’s own immune system to combat malignant disease. Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have produced durable responses in a subset of patients, raising hopes for long-term cancer control. However, for most patients, these therapies offer limited benefit, as tumors evolve mechanisms to evade immune surveillance.
This article was originally published on MedicalXpress.com

